Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 378

Similar articles for PubMed (Select 19155953)

1.

Cervical cancers after human papillomavirus vaccination.

Beller U, Abu-Rustum NR.

Obstet Gynecol. 2009 Feb;113(2 Pt 2):550-2. doi: 10.1097/AOG.0b013e318191a54a.

PMID:
19155953
2.

Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP).

MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.

3.

Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.

Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE.

J Natl Cancer Inst. 2009 Apr 1;101(7):475-87. doi: 10.1093/jnci/djn510. Epub 2009 Mar 24.

4.

Quadrivalent human papillomavirus vaccine.

Barr E, Tamms G.

Clin Infect Dis. 2007 Sep 1;45(5):609-7. Epub 2007 Jul 25. Review.

5.

Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.

Rambout L, Hopkins L, Hutton B, Fergusson D.

CMAJ. 2007 Aug 28;177(5):469-79. Epub 2007 Aug 1. Review.

6.
7.
8.

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.

FUTURE II Study Group.

N Engl J Med. 2007 May 10;356(19):1915-27.

9.

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years.

Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, James M, Vuocolo S, Hesley TM, Barr E.

J Infect Dis. 2009 Apr 1;199(7):936-44. doi: 10.1086/597309.

10.

Indications and efficacy of the human papillomavirus vaccine.

Hakim AA, Lin PS, Wilczynski S, Nguyen K, Lynes B, Wakabayashi MT.

Curr Treat Options Oncol. 2007 Dec;8(6):393-401. doi: 10.1007/s11864-007-0050-0. Review.

PMID:
18172770
11.

[Prevention of cervical cancer (II): prophylactic HPV vaccination, current knowledge, practical procedures and new issues].

Monsonego J.

Presse Med. 2007 Apr;36(4 Pt 2):640-66. Epub 2007 Mar 12. Review. French. Erratum in: Presse Med. 2007 Jul-Aug;36(7-8):1150-1.

PMID:
17350792
12.

Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.

Villa LL.

Int J Infect Dis. 2007 Nov;11 Suppl 2:S17-25. doi: 10.1016/S1201-9712(07)60017-4. Review.

13.

[Human papillomavirus: a vaccine against cervical carcinoma uterine].

Franceschi S.

Epidemiol Prev. 2002 May-Jun;26(3):140-4. Italian.

PMID:
12197051
14.

Efficacy of human papillomavirus vaccines: a systematic quantitative review.

Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC, Zanini RR.

Int J Gynecol Cancer. 2009 Oct;19(7):1166-76. doi: 10.1111/IGC.0b013e3181a3d100. Review.

PMID:
19823051
15.

[Human papillomavirus vaccines].

Brun JL.

J Gynecol Obstet Biol Reprod (Paris). 2008 Feb;37 Suppl 1:S155-66. doi: 10.1016/j.jgyn.2007.11.019. Epub 2008 Jan 9. Review. French.

16.

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.

Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Sings HL, James M, Hesley TM, Barr E.

J Infect Dis. 2009 Apr 1;199(7):926-35. doi: 10.1086/597307.

17.

Cervical cancer prevention in the human papilloma virus vaccine era.

Ghazal-Aswad S.

Ann N Y Acad Sci. 2008 Sep;1138:253-6. doi: 10.1196/annals.1414.030.

PMID:
18837904
18.

Human papillomavirus vaccines.

Satyaprakash A, Creed R, Ravanfar P, Mendoza N.

Dermatol Ther. 2009 Mar-Apr;22(2):150-7. doi: 10.1111/j.1529-8019.2009.01227.x. Review.

PMID:
19335726
19.

Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer.

Julius JM, Ramondeta L, Tipton KA, Lal LS, Schneider K, Smith JA.

Pharmacotherapy. 2011 Mar;31(3):280-97. doi: 10.1592/phco.31.3.280. Review.

PMID:
21361739
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk